C. Zarwan

发表

Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease.

D. Kazi, F. Resnic, K. Rieger-Christ, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

A. Tan, C. Anders, J. Graham, 2019, JAMA oncology.

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update

G. Rosner, J. Griggs, G. Lyman, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells1

D. Kufe, D. Avigan, J. Rosenblatt, 2008, The Journal of Immunology.

Immunomodulatory effects of vitamin D: implications for GVHD

D. Kufe, R. Ahmad, V. Boussiotis, 2010, Bone Marrow Transplantation.

Longitudinal study of breast cancer risk markers

S. Sharifi, S. Pories, M. Ghebremichael, 2020, The breast journal.

Early‐Onset 5‐Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate

F. Nugent, C. Zarwan, Brigitte Gil, 2016, Pharmacotherapy.

A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors

M. Birrer, N. Horowitz, William H. Barry, 2022, International Journal of Clinical Oncology.

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

A. Tan, C. Anders, M. Mita, 2018 .

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

Percy Ivy, A. Berkenblit, S. Cannistra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.

S. Sharifi, A. Agarwal, A. Kuliopulos, 2013, Cancer research.

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.

D. Lake, C. Hudis, L. Norton, 2009 .

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

R. Claus, A. von Heydebreck, J. Gulley, 2018, Journal of Immunotherapy for Cancer.

Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28

D. Neuberg, D. Kufe, K. Stevenson, 2010, Journal of immunotherapy.

Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced With Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC)

D. Kufe, R. Ahmad, D. Avigan, 2012, Journal of immunotherapy.

Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812)

P. Brown, L. Minasian, L. Ford, 2019, Cancer Prevention Research.

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

S. Lipshultz, R. Patten, A. Barac, 2019, Cardio-Oncology.

836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

A. Tolcher, K. Papadopoulos, R. Mosher, 2020 .

CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma.

D. Kufe, D. Avigan, J. Rosenblatt, 2009 .

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

A. Tolcher, T. Burns, Melissa L. Johnson, 2020 .

CT-011, Anti PD-1 Antibody, Enhances Ex-Vivo T Cell Responses To Autologous Dendritic/Myeloma Fusion Vaccine Developed For The Treatment Of Multiple Myeloma

D. Kufe, D. Avigan, J. Rosenblatt, 2010 .

Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.

S. Sharifi, A. Agarwal, A. Kuliopulos, 2013, Cancer research.